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doi:10.1016/j.gmbhs.2012.03.001Abstract This study investigated the hepatoprotective activity of the polyherbal formulation
Livshis in CCl4-induced hepatotoxic male albino rats, and included an assessment of the
toxicity of the formulation. Male Wistar albino rats (140  10 g) were divided into five groups
(nZ 6). Liver necrosis was induced by intraperitoneal injection of CCl4 (1 mL/kg body weight,
50% v/v with olive oil). Antioxidant enzyme activities, such as lipid peroxidation, and liver
function test biosensors were assessed. Hematological and renotoxicity markers were evalu-
ated to assess the general toxicity of the formulation. For acute toxicity evaluation of Livshis,
the formulation was administered orally at doses ranging from 25 to 3200 mg/kg body weight.
Hepatic antioxidant enzyme activities diminished significantly, and hepatic lipid peroxidation
rates were elevated in CCl4-treated animals that were pretreated with distilled water (Group
II). The activities of serum toxicity marker enzymes and serum liver function test biosensors
increased significantly in Group II animals, whereas these biosensors were significantly pro-
tected in Livshis pretreated, CCl4-treated animals. Group V animals, treated with Livshis
alone, did not exhibit any significant variation in levels of hematological and renotoxicity
markers compared to controls. In an acute toxicity study, there were no toxic symptoms up
to the dose level of 3200 mg/kg body weight. We conclude that Livshis is safe for long-term
treatment for hepatic protection at doses of 50 mg/kg body weight.
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.of Bio-Medical Laboratory Science & Management (UGC Innovative Funded Department), Vidyasagar
hoo.co.in (D. Ghosh).
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antioxidant properties and is used in the managementExposure to various organic compounds, including a number
of drugs and environmental pollutants, can cause cellular
damage by metabolic activation of those compounds to
form highly reactive substances such as reactive oxygen
species (ROS). The industrial solvent CCl4 is a well-
established hepatotoxin.1,2 The importance of medicinal
plants in traditional healthcare practices, providing clues
to new areas of research and in biodiversity conservation, is
now well recognized. However, information on the medic-
inal uses of plants is not always available in isolated areas
of India.3 In India, >43% of flowering plants are reported to
be of medicinal importance. Herbal medicines are popular
remedies for diseases, and are used by the vast majority of
the population worldwide. The pharmacological effects of
many plants have received much attention by researchers,
and in India, herbal formulations that have attained
widespread acceptability as therapeutic agents include
antidiabetics, hepatoprotective agents, and lipid-reducing
agents. However, there are many limitations such as
collection, storage, doses, and duration regarding the
safety and efficacy of these preparations.4 Livshis is
a hepatoprotective polyherbal formulation containing
seven medicinal plant parts; it is used in traditional
medicine to treat hepatic disorders. In the state of West
Bengal, India, the Livshis polyherbal formulation is used in
Ayurvedic medicine for the treatment of hepatic disor-
ders. Its constituents are Aloe barbadensis Mill., Androg-
raphis paniculata Wall. ex Nees., Asteracantha longifolia
Nees., Berberis chitria Lindl., Fumaria parviflora Lam.,
Phyllanthus fraternus Webs. and Picrorhiza kurroa Royle
ex Benth. (Table 1). A. barbadensis Mill. has been linked
with improved blood glucose levels in diabetes and
improvements in acute hepatitis.5,6 A. paniculata Wall. ex
Nees. is used by traditional Siddha and Ayurvedic systems
of medicine, and in tribal medicine in India and other
countries, for multiple clinical applications.7 The leaves
and roots of A. longifolia Nees. are used for the treat-
ment of hepatic obstruction, jaundice, and diseases of
the urinogenital tract.8 The stem, roots and fruits of B.
chitria Lindl. are used in many Ayurvedic preparations.
The Stem bark of B. chitria is used for the treatment of
malaria, diarrhea, and jaundice.9 Fresh and dried leaves,
and fresh juice from the whole F. parviflora Lam. plant
have been widely used in traditional remedies and folk-
lore medicines for liver disorders.10 P. fraternus Webs.Table 1 Composition of the Livshis polyherbal formulation.
Botanical name Family Vou
Aloe barbadensis Mill. Liliaceae RKB
Andrographis paniculata Wall. ex Nees. Acanthaceae RKB
Asteracantha longifolia Nees. Acanthaceae RKB
Berberis chitria Lindl. Berberidaceae RKB
Fumaria parviflora Lam. Fumariaceae RKB
Phyllanthus fraternus Webs. Euphorbiaceae RKB
Picrorhiza kurroa Royle ex Benth. Scrophulariaceae RKBhas a long history as an herbal medicine; it exhibits
of kidney stones, gallbladder stones, tuberculosis, and
hepatitis.11,12 P. kurroa Royle ex Benth. is used to treat
diabetes, jaundice, hepatomegaly, spleen disorders, and
skin disorders.13 Inspite of the past reputation of Livshis
as a medicine at the local level, the scientific basis of its
mode of action on hepatoprotective activity and toxicity
profile have not been investigated. We investigated the
toxicity and hepatoprotective effects of Livshis to assess
its safety and tolerability profile for long-term treatment.
Materials and methods
Preparation of the Livshis polyherbal formulation
The Pharmaceutical Division of Southern Health Improve-
ment Samity (SHIS; West Bengal, India) provided the seven
medicinal plants used in the preparation of Livshis. Prof.
R. K. Bhakat, Department of Botany and Forestry, Vidyasagar
University, West Bengal, India, taxonomically identified the
plants. Herbal specimens were kept as dried samples by the
DepartmentalHerbariumMuseum.Table 1 lists theherbarium
specimen numbers of these plants.
Selected parts of seven medicinal plants (Table 1) were
dried in an incubator for 24 hours at 37 C, then crushed
separately with an electrical grinder and pulverized.
Powdered forms of the plant parts were combined in fixed
ratios as per Table 1, and labeled Livshis. This preparation
of the Livshis polyherbal formulation was carried out
according to a proposed Ayurvedic hepatoprotective
formulation.14
Selection of animals and animal care
The hepatoprotective study was conducted using 30 mature
male Wistar albino rats weighing 140 10 g. Forty-eight rats
(140  10 g) were selected for the acute toxicity study.
Animals were acclimated to laboratory conditions for 15 days
prior to beginning the experiment. Rats were housed in
Tarsons cages at an ambient temperature of 25  2 C with
a 12-hour light:dark cycle. Rats were fed food and water ad
libitum. The Principles of Laboratory Animal Care were
followed throughout the duration of the experiment, and
instructions regarding injection and other treatment proce-
dures as provided by our Institutional Ethical Committee.15cher specimen Common
name
Parts used Amount present
in 450 mg Livshis
sample
-BMLSM-11/10 Ghritkumari Leaves 50 mg
-BMLSM-12/10 Kalmegh Leaves 60 mg
-BMLSM-13/10 Kulekhara Leaves 90 mg
-BMLSM-14/10 Darhaldi Bark, stem 80 mg
-BMLSM-15/10 Khetpapra Leaves 50 mg
-BMLSM-16/10 Bhuiamla Leaves 70 mg
-BMLSM-17/10 Picrorhiza Rhizomes 50 mg
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Rats in a fasting state were treated orally by forceful
gavage with 50 mg Livshis powder suspended in 5 mL
distilled water per kilogram body weight. This dose was
selected from our pilot study using doses from 20 mg/kg to
200 mg/kg, in which the present dose of 50 mg/kg was
noted as the threshold dose. In traditional medicine, Livshis
is given to humans at a dose of 20e30 mg/kg body weight
(2e3 mg/100 g body weight).
Livshis hepatoprotective study and chronic toxicity
assessment
Male Wistar albino rats weighing 140  10 g were divided
into five groups (n Z 6) for assessment of the Livshis
hepatoprotective effect and its general toxicity. Group I
(placebo control): rats were fed by per oral (p.o.) with 5 mL
distilled water/ kg body weight each day for 28 days under
fasting conditions. Group II [pretreatment (distilled water)
and CCl4 treatment]: rats were fed by per oral (p.o.) with
5 mL distilled water/ kg body weight for 27 days and on day
28, they received a single intraperitoneal injection of
0.5 mL/kg CCl4, 50% v/v with olive oil (1 mL total). Group III
(pretreatment with Livshis and CCl4 treatment): rats were
treated with 50 mg Livshis in 5 mL distilled water per
kilogram body weight each day under fasting conditions for
27 days. On day 28, each rat received a single intraperito-
neal injection of 0.5 mL/kg CCl4, 50% v/v with olive oil
(1 mL total). Group IV [pretreatment (Silymarin) and CCl4
treatment]: rats were treated with 20 mg Silymarin in 5 mL
distilled water per kilogram body weight each day under
fasting conditions for 27 days by gavage. On day 28, each
rat received a single intraperitoneal injection of 0.5 mL/kg
CCl4, 50% v/v with olive oil (1 mL total). Group V (distilled
water þ Livshis): rats were fed 50 mg Livshis in 5 mL
distilled water per kilogram body weight by gavage each
day for 28 days under fasting conditions.
All animals were rested, with no treatment on day 29 of
the experiment. Animals were observed daily for toxic
effects, mortality, body weight, food intake, and water
intake. On day 30 of the experiment, the final body weights
were recorded, and all the animals were sacrificed by light
ether anesthesia followed by decapitation. Approximately
6 mL blood was collected from the dorsal aorta of each rat.
Two milliliters of 6-mL sample were dispensed into EDTA for
hematological study, and the remaining 4 mL into heparin
for biochemical analysis. The liver and kidneys were
excised and weighed. Liver tissue samples were stored in
Bouin’s fixative for histological study. Remaining hepatic
tissue was stored at e20 C for assay of catalase (CAT),
glutathione-S-transferase (GST), super oxide dismutase
(SOD), and vitamin C antioxidant enzyme activities, and for
quantification of thiobarbituric acid reactive substances
(TBARS) using standard protocols.16e20
Liver function test parameters
For liver function tests (LFTs), we determined levels of
serum total bilirubin (TB), total protein (TP), and activities
of serum glutamic oxaloacetic transaminase (SGOT), serumglutamic pyruvate transaminase (SGPT), and alkaline
phosphatase (ALP) using standard kits.21e24
Histopathological study of liver
Liver tissues were dissected out from all the groups and
fixed in Bouin’s fixative. After 24 hours, small pieces of liver
tissue were dehydrated in an ascending series of ethanol
solutions. The tissues were subjected to paraffin embedding
and 5-mm sections were cut with a Leica microtome.
Deparaffinized sections were stained with hematoxylin and
eosin. Histological examinations were carried out on stained
sections with a computer-aided microphotography system
(Caliper pro, Dewinter Software Inc., Delhi, India).25
Renotoxicity biosensors
Levels of serum urea, uric acid, creatinine, and blood urea
nitrogen (BUN) were determined using commercially avail-
able standard kits (Span Diagnostic Ltd., Surat, India) for
assessment of renotoxicity biosensors.26e28
Hematotoxicity markers
Hemoglobin (Hb), red blood cell (RBC) count, total leuko-
cyte count (TLC), platelet index (PI), packed cell volume
(PCV), and erythrocyte sedimentation rate (ESR) were
determined using standard techniques.29
Study of acute toxicity of Livshis
An acute toxicity study (LD50 determination) was carried
out by the method described by Mythilpriya et al,30
in which 48 healthy male Wistar albino rats weighing
roughly 140  10 g were randomly distributed to eight
different groups of six animals each. The animals were
fasted overnight and Livshis was administered orally at
a dose of 25, 50, 100, 200, 400, 800, 1600 or 3200 mg/kg
body weight each day. During the Livshis treatment, all
animals were observed for awareness, interactivity,
posture, tremors, salivation, diarrhea, lethargy, sleep,
coma, and death in addition to continuous observation
from the first 4 hours, up until 14 days to determine
mortality rate.31
Statistical analysis
Analysis of variance followed by multiple comparison two-
tail t test was used for statistical analysis of collected
data.32 Differences were considered significant for p < 0.05
and p < 0.001. All the values shown in tables are
mean  standard error of the mean.
Results
Body weight and organo-somatic indices
Group II rats exhibited significantly increased organo-
somatic indices following treatment with CCl4; specifi-
cally, hepato-somatic and reno-somatic indices (p < 0.001),
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control animals. Livshis (Group III) and Silymarin (Group IV)
pretreated animals showed significantly reduced effects in
response to CCl4 exposure. Group V Livshis-treated control
animals showed insignificant changes in final body weight,
and hepato-somatic and reno-somatic indices with respect
to controls (Table 2).
Hepatic antioxidant enzyme activities and lipids
peroxidation level
Vitamin C levels and activities of hepatic antioxidant
enzymes CAT, GST and SOD biosensors were significantly
decreased (p < 0.001). There was an accompanying
elevation of lipids with oxidation level, that is, TBARS
biosensor, in Group II rats compared to the placebo
controls. Group III animals pretreated with Livshis exhibited
less dramatic changes in response to treatment with CCl4,
and so received significant protection from the pretreat-
ment regime (Table 3). There were insignificant differences
in biosensor data between Livshis (Group III) and Silymarin
(Group IV) pretreated rats. Livshis treatment alone, as
provided to control Group V rats, had no noticeable effect
on the activities of the enzyme and lipid peroxidation
biosensors (Table 3).
LFT biosensors
Group II rats, exposed to CCl4 with only distilled water
pretreatment, exhibited significant increases (p < 0.001) in
LFT parameters: serum TB, SGOT, SGPT and ALP, along with
a reduction in the level of serum TP. Group III animals, with
Livshis pretreatment, showed significant protection of LFT
biosensor activities. There were insignificant variations in
LFT biosensor data between Livshis and Silymarin pre-
treated Groups III and IV. Livshis treatment of the Group V
control animals produced no significant differences in the
LFT biosensors compared to the placebo control animals
(Table 4).
Histopathological evaluation
The histological profile of the hepatic tissue of the placebo
control animals showed a normal lobular architecture.
Normal hepatocytes were arranged in single cell cords
radiating away from a central vein (A). Group II rats, treatedTable 2 Effect of Livshis polyherbal formulation on body weight
male albino rats.
Groups Body weight (g)
Initial Final
(I) Placebo control 143.42  4.73 156.74  5.62
(II) Distilled water þ CCl4 146.64  4.77 124.82  5.21*
(III) Livshis þ CCl4 147.55  5.26 152.98  5.38
(IV) Silymarin þ CCl4 145.37  4.87 153.03  4.94
(V) Distilled water þ Livshis 141.34  5.58 157.65  4.88
All values are expressed as mean  standard error of the mean, n Z
t test.
* p < 0.001 compared with placebo control Group I.with distilled water and CCl4, showed disturbed liver
architecture, exhibiting central lobular necrosis with tiny
vacuoles, and fatty infiltrations (B). Group III and IV animals,
pretreated with Livshis and Silymarin respectively, and
subsequently treated with CCl4 retained normal hepatic
tissue architecture, so received significant protection from
CCl4-induced hepatic damage (C and D). Group V animals,
treated with Livshis alone, did not show any significant
hepatic tissue architectural changes (E) (Fig. 1).
Renotoxicity biosensors
Group II animals showed significant elevation in renotox-
icity biosensors urea, uric acid and creatinine levels in
blood, and BUN. Group III rats, receiving Livshis pretreat-
ment, acquired significant protection from the effects of
CCl4, as shown by the renotoxicity biosensor results. There
were no significant differences in renotoxicity biosensor
measurements for Group III and IV rats receiving Livshis and
Silymarin pretreatment, respectively. Livshis treatment of
the Group V control animals did not produce any significant
differences in renotoxicity biosensor data compared to the
Group I placebo control group (Table 5).
Hematotoxicity markers
Group II rats exhibited decreases in Hb levels, RBC count,
TLC, PI, and PCV (p < 0.001). Additionally, ESR for this test
group was elevated. However, Group III and IV rats did not
exhibit any noticeable changes in these indicators. The
Livshis control group (Group V) showed no changes in these
hematotoxicity markers (Table 6).
Livshis acute toxicity study
In the acute toxicity study, treatment with Livshis alone did
not produce any lethal or toxic symptoms up to a dosage of
3200 mg/kg body weight. No mortality or morbidity
occurred in animals during the 14-day period following oral
administration for all Livshis doses. We observed no
tremors, salivation, diarrhea, sleep, coma, death, or
unusual behaviors such as walking backwards, and the
animals had a normal reaction to handling. The LD50 for oral
administration of Livshis was >3200 mg/kg body weight;
treatment with 50 mg/kg Livshis was well tolerated by theand organo-somatic indices in CCl4-induced hepatotoxicity in
Hepato-somatic index (g %) Reno-somatic index (g %)
3.90  0.36 1.31  0.03
6.07  0.31* 1.92  0.05*
3.94  0.28 1.33  0.04
3.92  0.33 1.29  0.03
3.88  0.27 1.32  0.04
6. Analysis of variance followed by multiple comparison two-tail
Table 3 Protective effect of Livshis on hepatic antioxidant enzyme activities and lipid peroxidation levels against CCl4-
induced hepatotoxicity in male albino rats.
Groups CAT (mM H2O2
consumption/mg
tissue/min)
SOD
(U/mg tissue)
GST
(mM/min/mg tissue)
Vitamin C
(mg/dL)
TBARS
(nM/mg tissue)
(I) Placebo control 9.43  0.54 2.74  0.17 1.85  0.04 16.21  1.77 42.63  3.16
(II) Distilled water þ CCl4 3.58  0.31* 1.03  0.06* 0.57  0.02* 7.63  1.31* 73.35  4.72*
(III) Livshis þ CCl4 9.37  0.36 2.31  0.14** 1.81  0.03 14.51  1.96** 51.28  4.25*
(IV) Silymarin þ CCl4 9.34  0.48 2.68  0.15 1.83  0.04 14.66  1.68** 49.81  4.38*
(V) Distilled water þ Livshis 9.45  0.52 2.73  0.18 1.82  0.05 16.19  2.04 43.22  3.46
All values are expressed as mean  standard error of the mean, n Z 6. Analysis of variance followed by multiple comparison two-tail
t test.
* p < 0.001.
** p < 0.05 compared with placebo control Group I.
CAT: catalase; GST: glutathione-S-transferase; SOD: superoxide dismutase; TBARS: thiobarbituric acid reactive substance.
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long-term treatment (Table 7).Discussion
Toxicological evaluation is carried out in experimental
animals to predict the toxicity and safety of drugs and plant
products for human use, and to produce guidelines for
a dose that is safe for humans. A World Health Organization
survey has indicated that worldwide 70e80% of the pop-
ulation relies on alternative medicines, mainly from herbal
sources, for their primary health care.33 We investigated
the hepatoprotective effects of Livshis against CCl4-
induced hepatotoxicity, and screened the general toxicity
of Livshis to assess its safety and tolerability for long-term
treatment. CCl4 is a well-known hepatotoxin that is widely
used to induce hepatotoxicity in laboratory animals.34 The
cytochrome P450 system forms the reactive metabolite
trichloromethyl radical (CCl3) from CCl4. As oxygen
concentration increases, any CCl3 radicals present in the
system react very rapidly with the oxygen to produce highly
reactive ROS, which in turn causes cell necrosis and
subsequent organ death.35
Oxidative damage to a cell induces lipid peroxidation
of cell membrane lipids. Studies have shown that acute or
chronic exposure of animals to CCl4 increases the rate of
formation of lipid peroxidation products such as TBARS orTable 4 Protective role of Livshis on liver function test biosens
Groups TB (mg/dL) TP (mg/dL)
(I) Placebo control 0.54  0.03 9.47  0.83
(II) Distilled water þ CCl4 1.42  0.06* 5.33  0.62*
(III) Livshis þ CCl4 0.55  0.04 9.38  0.67
(IV) Silymarin þ CCl4 0.56  0.03 9.40  0.91
(V) Distilled water þ Livshis 0.52  0.03 9.50  0.88
All values are expressed as mean  standard error of the mean, n Z
t test.
* p < 0.001.
** p < 0.05 compared with placebo control Group I.
ALP: alkaline phosphatase. SGOT: serum glutamate oxaloacetate tra
total bilirubin; TP: total protein.malondialdehyde.36 Some authors have postulated that
damage that occurs in hepatic tissue injury following
exposure to CCl4 is a result of lipid peroxidation.
37 In the
present study, the significant increases in TBARS levels seen
in Group II rats exposed to CCl4 indicate increased lipid
peroxidation, tissue damage, and subsequent failure of
antioxidant defence mechanisms that would otherwise
prevent the formation of excessive free radicals. Moreover,
histopathological changes such as central lobular necrosis,
seen as the formation of tiny vacuoles, and FI were
observed in hepatic tissue in Group II rats. Liver injury
disturbs the hepatocyte transport function, resulting in the
leakage of plasma membrane, thereby causing increased TB
and increased enzyme levels in serum. TB, SGOT, SGPT and
ALP enzymes are normally excreted in bile by the liver. In
the presence of hepatotoxin, the liver bile excretion
process becomes defective, resulting in increased enzyme
levels in the serum.38 Similarly, CAT, GST, SOD and vitamin
C antioxidants constitute a mutually supportive line of
defense against ROS.37 Decreased activities of these enzy-
matic and nonenzymatic antioxidant species seen in the
hepatic tissue of Group II rats also supports the suggestion
of a failure of antioxidant defense mechanisms. Such
a failure could cause accumulation of highly reactive free
radicals, leading to deleterious effects such as loss of
integrity and function of cell membranes.39 This is sup-
ported by the observation that CCl4 induces the generation
of hydroxyl radicals, peroxyl radicals, and superoxideors in CCl4-induced hepatotoxicity in male albino rats.
SGOT (IU/L) SGPT (IU/L) ALP (IU/L)
62.72  4.87 31.47  3.78 90.64  4.21
134.7  6.48* 81.72  5.24* 154.72  5.3*
68.03  5.21** 35.24  4.21** 94.85  4.57**
67.53  5.46** 37.03  4.63** 96.25  5.13**
64.21  5.21 33.16  4.11 91.61  4.33
6. Analysis of variance followed by multiple comparison two-tail
nsaminase; SGPT: serum glutamate pyruvate transaminase; TB:
Figure 1 Effect of Livshis on histopathological changes in male albino rat liver. (A) placebo control; (B) Pretreatment (distilled
water) þ CCl4 treatment; (C) Pretreatment (Livshis) þ CCl4 treatment; (D) Pretreatment (Silymarin) þ CCl4 treatment;
(E) Control þ Livshis. Hematoxylin and eosin stain, original magnification 400. CLN: central lobular necrosis; CV: central vein;
FI: fatty infiltration; NH: normal hepatocyte.
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and nonenzymatic antioxidants. Group III rats, pretreated
with Livshis, retained significant liver function following
treatment with CCl4. Thus, Livshis plays a vital role in the
maintenance of normal liver cell membrane function, pro-
tecting hepatic tissue against CCl4 toxicity by means of
suppressing the generation of free radicals in hepatic
tissue. It is possible that Livshis stabilizes the plasma
membrane of hepatocytes against CCl4, and helps to
maintain hepatocyte transport function by reducing the
formation of CCl3 and trichloromethyl peroxy radical
(CCl3OO) from CCl4. As a result, formation of ROS is
reduced (e.g., superoxide anion, H2O2, and hydroxyl radi-
cals). Moreover, there is inhibition of hepatocyte plasma
membrane lipids by these free radicals.Table 5 Effect of Livshis on renotoxicity biosensors against CC
Groups Urea (mg/dL) UA
(I) Placebo control 40.82  3.65 3.44
(II) Distilled water þ CCl4 67.52  3.88* 8.78
(III) Livshis þ CCl4 45.3  4.17** 3.53
(IV) Silymarin þ CCl4 43.95  4.02 3.51
(V) Distilled water þ Livshis 41.06  3.74 3.47
All values are expressed as mean  standard error of the mean, n Z
t test.
* p < 0.001.
** p < 0.05 compared with placebo control Group I.
BUN: blood urea nitrogen; UA: uric acid.The elevation in concentrations of renotoxicity markers
urea, uric acid, creatinine and BUN, together with the
reduction in serum TP concentration in Group II rats are
indicative of cellular leakage and loss of the functional
integrity of cell membranes in renal tissue.40,41 Livshis
treatment alone resulted in no significant changes in any of
the renotoxicity biosensors. The normal renotoxicity
biosensors indicate that Livshis did not interfere with renal
function or renal integrity. Analysis of blood parameters is
important for risk evaluation because changes in the
hematological system are predictive of toxicity. We
attributed the observed reductions in Hb, RBC, TLC, PI and
PCV, and elevation of ESR in Group II rats to destruction of
erythrocytes, reduction in the rate of erythrocyte forma-
tion, and disturbed hematopoiesis, and/or to enhancedl4-induced hepatotoxicity in male albino rats.
(mg/dL) BUN (mg/dL) Creatinine (mg/dL)
 0.03 19.06  2.31 0.65  0.006
 0.05* 31.53  3.26* 0.82  0.007*
 0.04 21.45  3.02 0.68  0.005**
 0.04 20.52  2.21 0.67  0.006
 0.04 19.17  1.97 0.67  0.005
6. Analysis of variance followed by multiple comparison two-tail
Table 6 Remedial effects of Livshis on hematotoxicity markers against CCl4-induced hepatotoxicity in male albino rats.
Groups Hb (%) RBC (106/mm3) TLC (103/mm3) PI (105/mm3) PCV (%) ESR (mm/1st h)
(I) Placebo control 13.2  0.46 7.28  0.31 5.21  0.08 2.86  0.04 38.46  3.4 7.86  0.25
(II) Distilled water þCCl4 7.8  0.32* 5.17  0.24* 3.46  0.07* 1.53  0.02* 27.62  3.2* 13.83  0.4*
(III) Livshis þ CCl4 12.8  0.38 7.22  0.27 5.18  0.06 2.82  0.03 32.8  4.1** 8.02  0.31
(IV) Silymarin þ CCl4 13.0  0.41 7.25  0.30 5.20  0.08 2.84  0.04 36.62  3.6 7.98  0.27
(V) Distilled water þ Livshis 13.4  0.52 7.31  0.31 5.22  0.06 2.87  0.03 38.51  3.8 7.85  0.26
All values are expressed as mean  standard error of the mean, n Z 6. Analysis of variance followed by multiple comparison two-tail
t test.
* p < 0.001.
** p < 0.05 compared with placebo control Group I.
ESR: erythrocyte sedimentation rate; Hb: hemoglobin; PCV: packed cell volume; PI: platelet index; RBC: red blood cell; TLC: total
leukocyte count.
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of Group III rats with Livshis resulted in no significant
changes in Hb, RBC, TC, PI, PCV or ESR. Thus, Livshis is
nontoxic to circulating red cells, and does not interfere
with their production. Hematopoiesis and leukopoiesis
remain unaffected, even though the hematopoietic system
is one of the most sensitive targets for toxic compounds and
is an important index for physiological and pathological
status assessment in humans and animals.43 Therefore, we
conclude that Livshis is not hematotoxic.
During the acute toxicity study, rats in all groups did not
exhibit any adverse effects at a Livshis dose of 3200 mg/kg.
The Organization for Economic Cooperation and Develop-
ment (OECD) guidelines for acute oral toxicity categorizes
an LD50 dose of 2000 mg/kg as unclassified, and hence the
Livshis formulation is considered to be safe.
The active phyto-ingredients present in Livshis stabilize
the plasma membranes of hepatocytes and help to maintain
their transport function. The formulation also facilitates
the repair of hepatic tissue by protecting serum marker
enzyme activities. The formulation was tolerated well at
the oral doses tested, and produced neither signs of clinical
toxicity, nor any evidence of hepato-, reno- or hema-
totoxicity. We demonstrated that Livshis is a nontoxic
hepatoprotective drug by investigating its acute and
general toxicities after oral intake. This study provides
valuable data on Livshis hepatoprotective activities and its
toxicity profile. This information should be useful for theTable 7 Determination of median lethal dose (MLD) (LD50)
for orally administered Livshis.
Dose of
Livshis
(mg/kg)
No. of
animals
used
No. of
survivors
No. of
deaths
MLD (LD50)
25 6 6 0
50 6 6 0
100 6 6 0
200 6 6 0
400 6 6 0
800 6 6 0
1600 6 6 0
3200 6 6 0 >3200 mg/kgplanning of future preclinical and clinical studies using the
Livshis formulation.
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